PTX3 and type 2 diabetes mellitus: Similarly, Pentraxin-3 levels were significantly lower in obese controls without CVD (0.21 ± 0.05 ng/mL) than in HFpEF patients with T2DM (0.84 ± 0.67 ng/mL, p = 0.031), but not than patients with T2DM (0.52 ± 0.35 ng/mL, p = 0.391), while levels between the two latter groups were also not significantly different (p = 0.176).